These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31064198)

  • 1. Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease.
    Ma SL; Tang NLS; Wat KHY; Tang JHY; Lau KH; Law CB; Chiu J; Tam CCW; Poon TK; Lin KL; Kng CPL; Kong HL; Chan TY; Chan WC; Lam LCW
    Am J Alzheimers Dis Other Demen; 2019 Aug; 34(5):302-307. PubMed ID: 31064198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
    Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.
    Cacabelos R; Llovo R; Fraile C; Fernández-Novoa L
    Curr Alzheimer Res; 2007 Sep; 4(4):479-500. PubMed ID: 17908053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease.
    Sonali N; Tripathi M; Sagar R; Velpandian T; Subbiah V
    Dement Geriatr Cogn Disord; 2014; 37(1-2):58-70. PubMed ID: 24107805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study.
    Miranda LF; Gomes KB; Silveira JN; Pianetti GA; Byrro RM; Peles PR; Pereira FH; Santos TR; Assini AG; Ribeiro VV; Tito PA; Matoso RO; Lima TO; Moraes EN; Caramelli P
    J Alzheimers Dis; 2015; 45(2):609-20. PubMed ID: 25589728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease.
    Coin A; Pamio MV; Alexopoulos C; Granziera S; Groppa F; de Rosa G; Girardi A; Sergi G; Manzato E; Padrini R
    Eur J Clin Pharmacol; 2016 Jun; 72(6):711-7. PubMed ID: 26952092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
    Noetzli M; Eap CB
    Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease.
    Zhong Y; Zheng X; Miao Y; Wan L; Yan H; Wang B
    Am J Med Sci; 2013 Mar; 345(3):222-6. PubMed ID: 22986607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A; Svensson AL
    Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is it personalized treatment of dementia based on the CYP2D6 gene polymorphism possible?].
    Chebotareva AD; Levin OS; Markov DD; Sychev DA; Grishina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(6. Vyp. 2):90-94. PubMed ID: 30346440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations.
    Noetzli M; Guidi M; Ebbing K; Eyer S; Zumbach S; Giannakopoulos P; von Gunten A; Csajka C; Eap CB
    Ther Drug Monit; 2013 Apr; 35(2):270-5. PubMed ID: 23503455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease.
    Lu J; Wan L; Zhong Y; Yu Q; Han Y; Chen P; Wang B; Li W; Miao Y; Guo C
    J Pharmacol Sci; 2015 Nov; 129(3):188-95. PubMed ID: 26603528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients.
    Varsaldi F; Miglio G; Scordo MG; Dahl ML; Villa LM; Biolcati A; Lombardi G
    Eur J Clin Pharmacol; 2006 Sep; 62(9):721-6. PubMed ID: 16845507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease.
    Cacabelos R
    Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):673-701. PubMed ID: 32520597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease.
    Haake A; Nguyen K; Friedman L; Chakkamparambil B; Grossberg GT
    Expert Opin Drug Saf; 2020 Feb; 19(2):147-157. PubMed ID: 31976781
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
    Lockhart IA; Mitchell SA; Kelly S
    Dement Geriatr Cogn Disord; 2009; 28(5):389-403. PubMed ID: 19893314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could
    Jasiecki J; Wasąg B
    Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31601022
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.